Summarized by Masters of Longevity from Life Biosciences.
The company closed financing to advance its partial epigenetic reprogramming platform and investigational eye-disease therapy.
Key Takeaways
- Proceeds support completion of ER-100’s Phase 1 study in optic neuropathies.
- The company expected the financing to fund operations into the second half of 2027.
- ER-100 remains investigational; the funding announcement does not establish clinical benefit.
